Evidence mapPaperPMID 41268405Full record

ArticleFrontiers in public health2025

Driving the future of value-based healthcare in the Gulf Cooperation Council: a roadmap for achieving sustainable access to specialty pharmaceuticals.

Anas Hamad, Ahmed Al-Jedai, Rita Ojeil, Abdulrazaq Sheikh Al-Jazairi, Adel AlAssy, Yazed S AlRuthia, Waiel Al Naeem, Hajer Almudaiheem, Mouza Alsaadi, Nada Alagil and 15 more

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Anas HamadPharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Ahmed Al-JedaiColleges of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.
Rita OjeilLife Sciences Solution, PDC-CRO, Dubai, United Arab Emirates.
Abdulrazaq Sheikh Al-JazairiClinical Trials Transformation Initiative Division, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Adel AlAssyPharmaceuticals Supply Chain Management, M42 Health, Abu Dhabi, United Arab Emirates.
Yazed S AlRuthiaDepartment of Clinical Pharmacy, College of Pharmacy, Riyadh, Saudi Arabia.
Waiel Al NaeemDepartment of Pharmacy, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates.
Hajer AlmudaiheemClinical Pharmacy, The Saudi Society of Clinical Pharmacy, Riyadh, Saudi Arabia.
Mouza AlsaadiDepartment of Health Economics and Insurance Policies, Dubai Health Authority, Dubai, United Arab Emirates.
Nada AlagilClinical Pharmacy, Council of Health Insurance, Riyadh, Saudi Arabia.
Lina WahbaAdult Oncology Unit and Pharmacy Department, Tawam Hospital, Abu Dhabi, United Arab Emirates.
Abdulmohsin MarghalaniPharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.
Amna Al HasharSultan Qaboos Comprehensive Cancer Center, University Medical City, Seeb, Oman.
Abdullah O AlShehryPharmacy Services Administration, King Fahad Medical City, Riyadh, Saudi Arabia.
Sana AlblooshiDepartment of Pharmacy, Tawam Hospital, SEHA-Abu Dhabi Health Services, Al Ain, United Arab Emirates.
Ibtisam AlharbiPharmacoeconomic Centre, King Fahd Ahmed Forces Hospital, Jeddah, Saudi Arabia.
Marleine Bejjani MoukarzelDepartment of Pharmacy, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.
Sara AlbalushiPharmaceutical Care Department, Directorate General of Medical Supplies, Ministry of Health, Muscat, Oman.
Ahmed M El-SheashaeyPharmacy Department, Kuwait Cancer Control Centre, Al Sabah Specialized Medical District, Ministry of Health, Shuwaikh, Kuwait.
Mohammed A AseeriClinical Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
Farid AlenezyPharmacy Department, Kuwait Cancer Control Centre, Al Sabah Specialized Medical District, Ministry of Health, Shuwaikh, Kuwait.
Fathea AdheirPharmacy Department, Sidra Medicine, Ar-Rayyan, Qatar.
Abdulrahman AloumiPricing Department, Pharmaceutical and Herbal Medicine Registration and Control Administration, Ministry of Health, Kuwait City, Kuwait.
Rehab AlnoaimiProcurement, SHIFA National Medical Stores, Manama, Bahrain.
Khalid A AlnaqbiRheumatology Division, Sheikh Tahnoon Medical City, SEHA/Pure Health, Al Ain, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gulf Cooperation Council (GCC) countries are undergoing a critical transformation in their healthcare systems. This empowers them to address the rising burden of complex diseases, including rare diseases, cancer, neurological disorders, and immunological illnesses, which involve a high cost of therapy. A strategic shift from volume- to value-based healthcare (VBH) emphasizes sustainability, enhanced accessibility, and improved health outcomes through innovation. GCC's healthcare is marked by universal coverage and a shifting landscape of public-private partnerships. Rising pharmaceutical costs, especially for specialty drugs, continue to challenge budget sustainability. VBH offers a strategy to align healthcare expenditure with patient outcomes. This framework is supported by global and regional models such as managed entry agreements (MEAs), multi-criteria decision analysis, and real-world evidence (RWE). These models provide guidance for reimbursement strategies and support decision-making regarding high-value treatments. The GCC nations are also progressing towards policy discussion, but face challenges related to infrastructure, regulation, and workforce capacity. The Department of Health (DOH) in Abu Dhabi, which is a governmental health authority in the United Arab Emirates, has officially established a dedicated HTA unit to evaluate and assess new health technologies for evidence-informed decision making. This review highlights specialty care priorities and proposes target strategies such as expanding genetic databases, implementing screening programs, and establishing risk-sharing agreements to improve affordability, particularly for rare diseases. A consensus-driven phased roadmap for GCC-wide VBH adoption is recommended. This includes a focus on MEAs and patient-reported outcome measures, mid-term harmonization of health technology assessments (HTA) and RWE development as well as long-term establishment of digital ecosystems and value-based pricing platforms. Equitable and collaborative policies will be essential to achieving sustainable and inclusive healthcare systems across the GCC.

Indexed as

Delivery of Health CareHealth Services AccessibilityHumansMiddle EastValue-Based Health Careconsensus developmentGulf Cooperation Councilmanaged entry agreementspecialty drugsvalue-based healthcare

Identifiers

PMID41268405
PMCPMC12626995

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.